June 2026 Research Update

This month added a small but important piece of information about what it looks like to study NPC treatments in babies and toddlers: safety and drug exposure can be measured, but early signals of benefit are hard to interpret with only a few children. In five infants, arimoclomol (a medicine studied to support cell stress responses) added to miglustat was generally tolerated, yet one child stopped because of higher liver enzymes. Development and skills changed differently from child to child, so the study could not give a clear answer about whether the added drug helps at this age. [1]

The clearest result was that arimoclomol levels in the body looked similar to what has been seen in older people with NPC, which supports the dosing approach used in this substudy. Side effects were common (as often happens when infants with complex conditions are monitored closely), and most were mild or moderate, but there were also serious events in two children and one probable drug-related liver enzyme increase that led to withdrawal. Because the substudy was open-label and had no comparison group, it was designed mainly to understand safety and dosing rather than to prove improvement. [1]

For families, this mostly matters as early-stage evidence about what is feasible and what risks may need close attention when testing treatments in infants. Right now, the study mainly adds information about short-term safety signals and confirms that the drug exposure in infants can be in the same range as older patients, while leaving the question of developmental benefit unanswered. What remains uncertain is whether starting arimoclomol earlier changes longer-term skills or disease course, because the numbers were very small and children did not follow the same developmental path in this report. [1]

These studies reinforced a practical reality for many families: NPC can look very different from one person to another, and researchers are still working on which lab measures are most consistent across that variety. In a single-center cohort, children and teens showed a wide range of starting problems, including liver, lung, neurologic, and psychiatric-onset presentations, and even siblings with the same gene changes could be quite different. Against that background of variability, two blood-related measures were notably consistent in that group: LysoSM-509 was elevated in all patients, and HDL cholesterol was low in most. [2]

The same cohort also discussed miglustat (a commonly used NPC medicine) in routine care and reported that some patients appeared stable, especially when started earlier, but the small and retrospective nature of the data limits firm conclusions. The main value of this report is less about proving how well a treatment works and more about mapping the range of real-world NPC presentations and highlighting which lab signals may be reliable across different symptom patterns. This kind of descriptive work can shape future studies by helping researchers choose markers to follow over time. [2]

A separate laboratory study explored why NPC1 and NPC2 forms of the disease might not behave identically inside cells, even though both involve lysosomal lipid buildup. In human cells edited to lack NPC1 or NPC2, only NPC1 loss led to a clear increase in contact points between mitochondria (energy-producing parts of the cell) and lysosomes (recycling parts), and a protein called HKDC1 rose sharply and could drive this change when increased. This is early, cell-based research, but it offers a possible explanation for subtype differences that could guide what scientists measure or target in future work. [3]

For patients and caregivers, the clinical cohort findings mostly matter now for understanding why experiences can be so different across individuals and even within the same family, and why tracking disease with a single symptom can be difficult. The consistent elevation of LysoSM-509 and the frequent finding of low HDL cholesterol are research-backed signals that may help researchers follow NPC across different presentations, although this report does not show how well these markers predict day-to-day changes or long-term outcomes. The cell study is earlier-stage and does not translate directly to patient care, but it helps clarify that NPC1 and NPC2 may have meaningful differences in how cells reorganize internally, which could influence future biomarker or treatment ideas if confirmed in people. [2] [3]